Tumor markers for early detection of ovarian cancer

Expert Review of Molecular Diagnostics

Volumn 10, Issue 6, 2010, Pages 787-798

  Ren, Juan ^a   Cai, Hui ^a   Li, Yi ^a   Zhang, Xiaozhi ^a   Liu, Zi ^a   Wang, Jian Sheng ^a   Hwa, Yi Lisa ^b   Zhang, Yuelang ^a   Yang, Ya ^a   Li, Yu ^a   Jiang, Shi Wen ^c  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b MERCER UNIVERSITY   (United States)

^c MAYO CLINIC   (United States)

Author keywords

diagnostic; early detection; early stage; ovarian cancer; tumor marker

Indexed keywords

APOLIPOPROTEIN A1; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; COLONY STIMULATING FACTOR 1; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; LYSOPHOSPHATIDIC ACID; MATRILYSIN; MESOTHELIN; MONOCLONAL ANTIBODY; PREALBUMIN; PROLACTIN; PROSTASIN; SOMATOMEDIN B; TRANSFERRIN; TUMOR MARKER; VASCULOTROPIN;

BIOTECHNOLOGY; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; COST EFFECTIVENESS ANALYSIS; EARLY DIAGNOSIS; GENE EXPRESSION; HUMAN; METABOLOMICS; MOLECULAR CLONING; MULTIGENE FAMILY; OVARY CANCER; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; VALIDATION PROCESS;

ANTIGENS, NEOPLASM; CLINICAL TRIALS AS TOPIC; EARLY DIAGNOSIS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; METABOLOME; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROTEOME; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 77956741345     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.10.39     Document Type: Review

References (93)

1. Bertone-Johnson ER. Epidemiology of ovarian cancer: a status report. Lancet 365, 101-102 (2005).
2. Ye B, Gagnon A, Mok SC. Recent technical strategies to identify diagnostic biomarkers for ovarian cancer. Expert Rev. Proteomics 4(1), 121-131 (2007).
3. Ebert MP, Korc M, Malfertheiner P et al. Advances, challenges, and limitations in serum-proteome-based cancer diagnosis. J. Proteome Res. 5, 19-25 (2006).
4. Jacobs IJ, Skates SJ, MacDonald N et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 353(9160), 1207-1210 (1999).
5. Nossov V, Amneus M, Su F et al. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? Am. J. Obstet. Gynecol. 199(3), 215-223 (2008).
6. Abstracts of the first scientific workshop of the Early Detection Research Network. Dis. Markers 17(1), 3-38 (2001).
7. Kabawat SE, Bast RC Jr, Bhan AK et al. Tissue distribution of acoelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int. J. Gynecol. Pathol. 2(3), 275-285 (1983).
8. Bast RC Jr. Status of tumor markers in ovarian screening. J. Clin. Oncol. 21(10), 200s-205s (2003).
9. Duffy MJ, Bonfrer JM, Kulpa J et al. CA125 in ovarian cancer: European Group on tumor markers guidelines for clinical use. Int. J. Gynecol. Cancer 15, 679-691 (2005).
10. Medeiros L, Rosa D, da Rosa M et al. Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review. Eur. J. Obstet. Gynecol. Reprod. Biol. 142(2), 99-105 (2009).
11. Skates SJ, Menon U, MacDonald N et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J. Clin. Oncol. 21(10 Suppl.), 206-210 (2003).
12. Menon U, Skates SJ, Lewis S et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J. Clin. Oncol. 23 (31), 7919-7926 (2005).
13. Menon U, Gentry-Maharaj A, Hallett R et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 10(4), 327-340 (2009).
14. Partridge E, Kreimer AR, Greenlee RT et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet. Gynecol. 113(4), 775-782(2009).
15. Gadducci A, Cosio S, Carpi A et al. Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed. Pharmacother. 58(1), 24-38 (2004).
16. Koprowski H, Steplesky Z, Mitchell K et al. Colorectal carcinoma antigensdetected by hybridoma antibodies. Somatic Cell Genet. 5, 957-972 (1979)
17. Gadducci A, Ferdeghini M, Prontera C et al. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis. Gynecol. Oncol. 44(2), 147-154 (1992).
18. Skates SJ, Horick N, Yu Y et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-13, CA 72-74, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J. Clin. Oncol. 22(20), 4059-4066 (2004).
19. Xu FJ, Yu YH, Daly L et al. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures. J. Clin. Oncol. 11(8), 1506-1510 (1993).
20. Woolas RP, Conaway MR, Xu F et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol. Oncol. 59(1), 111-116 (1995).
21. van Haaften-Day C, Shen Y, Xu F et al. OVX1, Macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma. Cancer 92(11), 2837-2844 (2001).
22. Xu Y, Fang XJ, Casey G et al. Lysophospholipids activate ovarian and breast cancer cells. Biochem. J. 309(3), 933-940 (1995).
23. Xu Y, Shen Z, Wiper DW et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 280(8), 719-723 (1998).
24. Sutphen R, Xu Y, Wilbanks GD et al. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 13(7), 1185-1191 (2004).
25. Sedláková I, Vávrová J, Tosner J et al. Lysophosphatidic acid: an ovarian cancer marker. Eur. J. Gynaecol. Oncol. 29(5), 511-514 (2008).
26. Tchagang AB, Tewfik AH, DeRycke MS et al. Early detection of ovarian cancer using group biomarkers. Mol. Cancer Ther. 7(1), 27-37 (2008).
27. Gorelik E, Landsittel DP, Marrangoni AM et al. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 14(4), 981-987 (2005).
28. Lokshin AE, Winans M, Landsittel D et al. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol. Oncol. 102(2), 244-251 (2006).
29. Oehler MK, Caffier H. Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer. Anticancer Res. 20, 5109-5112 (2000).
30. Cooper BC, Ritchie JM, Broghammer CL et al. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin. Cancer Res. 8, 3193-3197 (2002).
31. Peng XP, Li JD, Li MD et al. Clinical significance of vascular endothelial growth factor in sera of patients with gynaecologicant malignant tumors. Ai Zheng. 21,181-185 (2002).
32. Rosen DG, Wang L, Atkinson JN et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol. Oncol. 99(2), 267-277 (2005).
33. Kirchhoff C, Habben I, Ivell R, Krull N. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol. Reprod. 1991, 45(2), 350-357 (1991).
34. Moore RG, MacLaughlan S, Bast RC. Current state of biomarker development for clinical application in epithelial ovarian cancer. Gynecol. Oncol. 116(2), 240-245 (2010).
35. Hough CD, Sherman-Baust CA, Pizer ES et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 60(22), 6281-6287 (2000).
36. Ono K, Tanaka T, Tsunoda T et al. Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res. 60(18), 5007-5011 (2000).
37. Hellstrom I, Raycraft J, Hayden-Ledbetter M et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 63(13), 3695-3700 (2003).
38. Rapkiewicz AV, Espina V, Petricoin EF 3rd et al. Biomarkers of ovarian tumours. Eur. J. Cancer. 40(17), 2604-2612 (2004).
39. Lu KH, Patterson AP, Wang L et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin. Cancer Res. 10(10), 3291-3300 (2004).
40. Visintin I, Feng Z, Longton G et al. Diagnostic markers for early detection of ovarian cancer. Clin. Cancer Res. 14(4), 1065-1072 (2008).
41. Scholler N, Crawford M, Sato A et al. Bead-based ELISA for validation of ovarian cancer early detection markers. Clin. Cancer Res. 12(7 Pt 1), 2117-2124 (2006).
42. Moore RG, McMeekin DS, Brown AK et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol. Oncol. 112(1), 40-46 (2009).
43. Moore RG, Brown AK, Miller MC et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol. Oncol. 108(2), 402-408 (2008).
44. Mok SC, Chao J, Skates S et al. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J. Natl Cancer Inst. 93(19), 1458-1464 (2001).
45. Costa FP, Batista JEL, Zelmanowicz A et al. Prostatin, a potential tumor marker in ovarian cancer -a pilot study. Clinics 64(7), 641-644(2009).
46. Takahashi S, Suzuki S, Inaguma S, Ikeda Y, Cho YM, Hayashi N. Down-regulated expression of prostasin in high-grade or hormone-refractory human prostate cancers. Prostate 54, 187-193 (2003).
47. Chen M, Chen LM, Lin CY, Chai KX. The epidermal growth factor receptor (EGFR) is proteolytically modified by the Matriptase-Prostasin serine protease cascade in cultured epithelial cells. Biochim. Biophys. Acta. 1783, 896-903 (2008).
48. Wong KK, Cheng RS, Mok SC. Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system. Biotechniques 30(3), 670-675 (2001).
49. Kim JH, Skates SJ, Uede T et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 287(13), 1671-1679 (2002).
50. Scholler N, Fu N, Yang Y et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc. Natl Acad. Sci. USA 96(20), 11531-11536 (1999).
51. McIntosh MW, Drescher C, Karlan B et al. Combining CA125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol. Oncol. 95(1), 9-15 (2004).
52. Shah CA, Lowe KA, Paley P et al. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiol. Biomarkers Prev. 18(5), 1365-1372 (2009).
53. Badgwell D, Lu Z, Cole L et al. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free b subunit and urinary hCG b core fragment. Gynecol. Oncol. 106(3), 490-497 (2007).
54. Yousef GM, Diamandis EP. Tissue kallikreins: new players in normal and abnormal cell growth? Thromb. Haemost. 90(1), 7-16 (2003).
55. Yousef GM, Polymeris ME, Yacoub GM et al. Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res. 63(9), 2223-2227 (2003).
56. Shvartsman HS, Lu KH, Lee J et al. Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol. Oncol. 90(1), 44-50 (2003).
57. Adib TR, Henderson S, Perrett C et al. Predicting biomarkers for ovarian cancer using gene-expression microarrays. Br. J. Cancer. 90, 686-692 (2004).
58. Simon I, Zhuo S, Corral L et al. B7-H4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res. 66, 1570-1575 (2006).
59. Iorio MV, Visone R, Di Leva G et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 67(18), 8699-8707 (2007).
60. Bast RC Jr, Urban N, Shridhar V et al. Early detection of ovarian cancer: promise and reality. In: Ovarian Cancer. Stack MS, Fishman DA (Eds). Kluwer, Boston, MA, USA 61-97 (2002).
61. Zhang Z, Yu Y, Xu F et al. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol. Oncol. 107(3), 526-531 (2007).
62. Nakae M, Iwamoto I, Fujino T et al. Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer. J. Obstet. Gynaecol. Res. 32(3), 309-314 (2006).
63. Zhang Z, Bast RC Jr, Yu Y et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 64(16), 5882-5890 (2004).
64. Nosov V, Su F, Amneus M et al. Validation of serum biomarkers for detection of early-stage ovarian cancer. Am. J. Obstet. Gynecol. 200(6), 639-641 (2009).
65. Mor G, Visintin I, Lai Y et al. Serum protein markers for early detection of ovarian cancer. Proc. Natl Acad. Sci. 102, 7677-7682 (2005).
66. Ardekani AM, Akhondi MM, Sadeghi MR. Application of genomic and proteomic technologies to early detection of cancer. Arch. Iran. Med. 11(4), 427-434 (2008).
67. Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359 (9306), 572-577(2002).
68. Kong F, Nicole White C, Xiao X et al. Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer. Gynecol. Oncol. 100(2), 247-253 (2006).
69. Kozak KR, Su F, Whitelegge JP et al. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 5(17), 4589-4596 (2005).
70. Lin YW, Lin CY, Lai HC et al. Plasma proteomic pattern as biomarkers for ovarian cancer. Int. J. Gynecol. Cancer 16(1), 139-146 (2006).
71. Ye B, Skates S, Mok SC et al. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin. Cancer Res. 12(2), 432-441 (2006).
72. Zhang H, Kong B, Qu X et al. Biomarker discovery for ovarian cancer using SELDI-TOFMS. Gynecol. Oncol. 102(1), 61-66 (2006).
73. Faca VM, Ventura AP, Fitzgibbon MP et al. Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extracellular domains. PLoS ONE 3(6), e2425 (2008).
74. Pitteri SJ, JeBailey L, Faca VM et al. Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery. PLoS ONE 4(11), e7916 (2009).
75. Gortzak-Uzan L, Ignatchenko A, Evangelou AI et al. A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. J. Proteome Res. 7(1), 339-351 (2008).
76. Ross PL, Huang YN, Marchese JN et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell Proteomics 3, 1154-1169 (2004).
77. Gagné JP, Éthier C, Gagné P et al. Comparative proteome analysis of human epithelial ovarian cancer. Proteome Sci. 5, 16 (2007).
78. Kothandaraman N, Zhao CQ, Mahesh C. Ovarian cancer proteomics: many technologies one goal. Proteomics Clin. Appl. 2(2), 195-218 (2008).
79. Denkert C, Budczies J, Kind T et al. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res. 66, 10795-10804 (2006).
80. Nelson A, Francis JE, Zorbas H. Population screening and early detection of ovarian cancer in asymptomatic women. Aust. NZ J. Obstet. Gynaecol. 49, 448-450 (2009).
81. Anderson GL, McIntosh M, Wu Ll et al. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J. Natl Cancer Inst. 102, 26-38 (2010).
82. Williams TI, Toups KL, Saggese DA., Kalli KR, Cliby WA, Muddiman DC. Epithelial ovarian cancer: disease etiology, treatment, detection, and investigational gene, metabolite, and protein biomarkers. J. Proteome Res. 6, 2936-2962 (2007).
83. Sjovall K, Nilsson B, Einhorn N et al. The significance of serum CA 125 elevation in malignant and nonmalignant diseases. Gynecol. Oncol. 85(1), 175-178 (2002).
84. Buys SS, Partridge E, Greene MH et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am. J. Obstet. Gynecol. 193(5), 1630-1639 (2005) (Pubitemid 41540458)
85. Meinhold-Heerlein I, Brautigam K, Bauerschlag DO et al. Serum biomarkers for early detection of ovarian cancer. Geburtshilfe Frauenheilkd 68(8), 830-837 (2008).
86. Kim K, Visintin I, Alvero AB et al. Development and validation of a protein-based signature for the detection of ovarian cancer. Clin. Lab. Med. 29(1), 47-55 (2009).
87. Rai AJ, Zhang Z, Rosenzweig J et al. Proteomic approaches to tumor marker discovery -identification of biomarkers for ovarian cancer. Arch. Pathol. Lab. Med. 126(12), 1518-1526 (2002).
88. Ye B, Cramer DW, Skates SJ et al. Haptoglobin-a subunit as potential serum biomarker in ovarian cancer: Identification and characterization using proteomic profiling and mass spectrometry. Clin. Cancer Res. 9(8), 2904-2911 (2003).
89. Vlahou A, Schorge JO, Gregory BW et al. Diagnosis of ovarian cancer using decision tree classification of mass spectral data. J. Biomed. Biotechnol. 5, 308-314 (2003).
90. Liu CW, Shea N, Rucker S et al. Proteomic patterns for classification of ovarian cancer and CTCL serum samples utilizing peak pairs indicative of post-translational modifications. Proteomics 7(22), 4045-4052 (2007).
91. Assareh A, Moradi MH. Extracting efficient fuzzy if-then rules from mass spectra of blood samples to early diagnosis of ovarian cancer. Proceedings of the 2007 IEEE Symposium on Computational Intelligence in Bioinformatics and Computational Biology 502-506 (2007).
92. Lopez MF, Mikulskis A, Kuzdzal S et al. A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. Clin. Chem. 53(6), 1067-1074 (2007).
93. UK Collaborative Trial of Ovarian Cancer Screening. NCT00058032 www.clinicaltrials.gov